Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence. The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company. Get the full story at our sister site, Drug Delivery Business News.
Orexo AB
Medtronic touts heart failure treatment study | Research roundup
Medtronic Inc. (NYSE:MDT) said results from the Improve HF study demonstrate that select guideline-based outpatient heart failure measures can increase patient survival and might be useful for improving patient quality of care.
The Improve HF (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) study is the largest U.S.-based outpatient heart failure clinical study. The results of the study were published in the journal Circulation.